Candel therapeutics partners with the university of pennsylvania's center for cellular immunotherapies to study combinations of novel viral immunotherapy and car-t cell therapy in solid tumor models

Needham, mass., oct. 26, 2022 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl) (candel or the company), a clinical stage biopharmaceutical company developing viral immunotherapies, today announced a collaboration with the university of pennsylvania (penn) to study the impact of novel viral immunotherapies based on candel's proprietary enlighten™ discovery platform to strengthen the effects of penn's car-t cell therapies in solid tumor models.
CADL Ratings Summary
CADL Quant Ranking